HOME
PRODUCT
SOLUTION
SUPPORT
ABOUT
CONTACT
2024.05
Celnovte self-cloned primary antibodies won optimal in NordiQC assessment.
2021.06
Celnovte PR NordiQC Assessment, Class III NMPA certificate
Celnovte self-cloned primary antibodies won optimal in NordiQC assessment for 6 consecutive years. Celnovte got Class III NMPA certificate.
Celnovte HER2 NordiQC Assessment & Class III NMPA certificate
2021.05
Download Celnovte CDX2 NordiQC Assessment Documentation
Download Celnovte CD56 NordiQC Assessment Documentation